A practical reference on melanogenesis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-01. Anything still debated is marked as such rather than presented as settled.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Archaeological evidence indicates that the use of medicinal plants dates back to the Paleolithic age, approximately 60,000 years ago. Written evidence of herbal remedies dates back over 5,000 years to the Sumerians, who compiled lists of plants. Some ancient cultures wrote about plants and their medical uses in books called herbals. In ancient Egypt, herbs were mentioned in Egyptian medical papyri, depicted in tomb illustrations, or on rare occasions found in medical jars containing trace amounts of herbs. In ancient Egypt, the Ebers papyrus dates from about 1550 BCE, and covers more than 700 compounds, mainly of plant origin. The earliest known Greek herbals came from Theophrastus of Eresos who, in the 4th century BCE, wrote in Greek Historia Plantarum, from Diocles of Carystus who wrote during the 3rd century BCE, and from Krateuas who wrote in the 1st century BCE. Only a few fragments of these works have survived intact, but from what remains, scholars have noted an overlap with the Egyptian herbals. Seeds likely used for herbalism were found in archaeological sites of Bronze Age China dating from the Shang dynasty (c. 1600 – c. 1046 BCE). Over a hundred of the 224 compounds mentioned in the Huangdi Neijing, an early Chinese medical text, are herbs. Herbs were also commonly used in the traditional medicine of ancient India, where the principal treatment for diseases was diet. De Materia Medica, originally written in Greek by Pedanius Dioscorides (c. 40 – c.
The three substrates of this enzyme are alanine, water, and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are pyruvic acid, reduced NADH, ammonia, and a proton. This enzyme participates in taurine and hypotaurine metabolism and reductive carboxylate cycle (CO2 fixation).
== Role in Human Pathology == SUMO protein is implicated in the etiology of many biomedical disease states not limited to: cancer, atherosclerosis, cardiovascular disease, neurodegenerative disease, diabetes, liver disease, intestinal disorders, and even infectious disease. In the case of the well-studied cancer tumor suppressor known as p53, there is a regulatory ubiquitin ligase protein in humans called Mouse Double Minute 2 protein, or MDM2, which acts to remove p53 from the cell. MDM2 regulates itself through self-ubiquitination by way of a RING finger domain, targeting itself for proteasomal destruction. When it is SUMOylated at the RING finger domain, MDM2 no longer limits its own function in the cell. When protected from itself, it likewise ubiquitinates p53, marking the protective p53 for destruction instead, whose absence is understood to promote cancer. Here again, the base case is SUMOylation, which is actively being undone by newly discovered SUMO protease SUSP4 and also by the SUMO protease interaction of SMT3IP1/SENP3 which is understood to deSUMOylate both MDM2 and p53. One of the ways p53 functions is as a DNA-binding tetramer; interestingly, SUMOylation of p53 delocalizes it from the nucleus, which prevents such activity. The critical nature of p53 cannot be overstated: in fact, if a human carries only one non-functioning copy of p53, it results in a deadly cancer prognosis known as Li-Fraumeni syndrome.
== History == MD was originally developed in the early 1950s, following earlier successes with Monte Carlo simulations—which themselves date back to the eighteenth century, in the Buffon's needle problem for example—but was popularized for statistical mechanics at Los Alamos National Laboratory by Marshall Rosenbluth and Nicholas Metropolis in what is known today as the Metropolis–Hastings algorithm. Interest in the time evolution of N-body systems dates much earlier to the seventeenth century, beginning with Isaac Newton, and continued into the following century largely with a focus on celestial mechanics and issues such as the stability of the Solar System. Many of the numerical methods used today were developed during this time period, which predates the use of computers; for example, the most common integration algorithm used today, the Verlet integration algorithm, was used as early as 1791 by Jean Baptiste Joseph Delambre. Numerical calculations with these algorithms can be considered to be MD done "by hand".
=== 2016–2025: Hayden leadership === Appointed in 2016 by President Barack Obama, Carla D. Hayden was sworn in as the fourteenth librarian of Congress on September 14, 2016. She is the first professional librarian to hold the post since 1974, holding a Ph.D. in library science from the University of Chicago. She was the CEO of Enoch Pratt Free Library in Baltimore, Maryland, from 1993 until 2016, and president of the American Library Association (ALA) from 2003 to 2004. She also is the first woman and the first African American to hold the position. She continued the work of digitizing as much as possible of the collection and of expanding electronic access to the collection. She initiated programs to modernize the library, expand access from rural areas, and expanding the infrastructure and technological capacity of the library and assessment of her leadership of the library by the community reflects her expressed goals. The Association of Research Libraries noted Hayden's transformation of the library "into a more open, accessible, and celebrated U.S. institution, while reaffirming its role as the people’s library". The American Library Association characterized Hayden as a "wise and faithful steward of the Library of Congress – the library she has called our 'national treasure'".
Sources: en.wikipedia.org
Diaphoresis due to ectopic catecholamine is a classic symptom of a pheochromocytoma, a rare tumor of the adrenal gland. Acetylcholinesterase inhibitors (e.g. some insecticides) also cause contraction of sweat gland smooth muscle leading to diaphoresis. Mercury is well known for its use as a diaphoretic, and was widely used in the 19th and early 20th century by physicians to "purge" the body of an illness. However, due to the high toxicity of mercury, secondary symptoms would manifest, which were erroneously attributed to the former disease that was being treated with mercurials. Infantile acrodynia (childhood mercury poisoning) is characterized by excessive perspiration. A clinician should immediately consider acrodynia in an afebrile child who is sweating profusely. Some people can develop a sweat allergy. The allergy is not due to the sweat itself but instead to an allergy-producing protein secreted by bacteria found on the skin. Tannic-acid has been found to suppress the allergic response along with showering.
=== Empirical methods === A set of empirical rules relating the protein structure to the pKa values of ionizable residues have been developed by Li, Robertson, and Jensen. These rules form the basis for the web-accessible program called PROPKA for rapid predictions of pKa values. A recent empirical pKa prediction program was released by Tan KP et.al. with the online server DEPTH web server.
=== Block copolymers === A common application of block copolymers is to develop thermoplastic elastomers (TPEs). Early commercial TPEs were developed from polyurethranes (TPUs), consisting of alternating soft segments and hard segments, and are used in automotive bumpers and snowmobile treads. Styrenic TPEs entered the market later, and are used in footwear, bitumen modification, thermoplastic blending, adhesives, and cable insulation and gaskets. Modifying the linkages between the blocks resulted in newer TPEs based on polyesters (TPES) and polyamides (TPAs), used in hose tubing, sport goods, and automotive components. Amphiphilic block copolymers have the ability to form micelles and nanoparticles. Due to this property, amphiphilic block copolymers have garnered much attention in research on vehicles for drug delivery. Similarly, amphiphilic block copolymers can be used for the removal of organic contaminants from water either through micelle formation or film preparation.
The brand name featured on the label is usually the same as the distillery name (for example, the Talisker distillery labels its whiskies with the Talisker name). Indeed, the SWR prohibits bottlers from using a distillery name when the whisky was not made there. A bottler's name may also be listed, sometimes independent of the distillery. In addition to requiring that Scotch whisky be distilled in Scotland, the SWR requires that it also be bottled and labelled in Scotland. Labels may also indicate the region of the distillery (for example, Islay or Speyside). Alcoholic strength is expressed on the label by Alcohol By Volume (ABV) or sometimes simply "Vol". Typically, bottled whisky is between 40% and 46% ABV. Whisky is considerably stronger when first emerging from the cask—normally 60–63% ABV. Water is then added to create the desired bottling strength. If the whisky is not diluted before bottling, it can be labelled as cask strength. A whisky's age may be listed on the bottle providing a guarantee of the youngest whisky used. An age statement on the bottle, in the form of a number, must reflect the age of the youngest whisky used to produce that product. A whisky with an age statement is known as guaranteed age whisky. Scotch whisky without an age statement may, by law, be as young as three years old. In the early 21st century, such "No age statement" whiskies have become more common, as distilleries respond to the depletion of aged stocks caused by improved sales. A label may carry a distillation date or a bottling date.
Sources: en.wikipedia.org
=== 6.5% salt broth === The 6.5% salt broth test is used to analyze the tolerance level of various bacteria under halophilic conditions. This test is used because most organisms cannot survive in high salt concentrations while Staphylococci, Enterococci, and Aerococci are all expected to tolerate 6.5% NaCl concentrations.
On April 2, 2011, a month and a half before the municipal elections and autonomous communities elections were held, Zapatero, under pressure from his own party, announced that he would not be the head of the list in the next general elections. However, Zapatero's resignation did not prevent the Socialist landslide in the municipal and autonomic elections, as the PSOE was 10 points behind the People's Party. Shortly afterwards the PSOE named Alfredo Pérez Rubalcaba as its new candidate for the presidency of government. The Sunday before the celebration of the municipal and autonomic elections, May 15, 2011, there were demonstrations of "outraged" ones, mostly young people, in the main Spanish cities called by the grassroots organization "¡Democracia Real YA!". The next day, a group of them decided to camp in the Puerta del Sol in Madrid and the eviction by the police only increased the number of campers who ended up occupying the entire square and getting great national and international media coverage, in addition to their example quickly spread to the squares of many cities. There they remained for several weeks. One of the most repeated slogans in the assemblies they held was "¡No nos representan!" ("They don't represent us!") in reference to the big political parties. Thus was born what would become known as the 15-M movement.
These studies, generally small and often single-center with short- to mid-term follow-up, report that laser-based techniques may be associated with reduced postoperative pain, shorter operative time, shorter hospital stay, faster wound healing, and improved cosmetic outcomes, with recurrence rates broadly comparable to conventional surgery in the short term. Systematic reviews and meta-analyses of laser treatment in pilonidal disease report primary healing rates of approximately 80–85% and relatively low complication rates, with recurrence rates varying depending on follow-up duration and study design. A broader meta-analysis of minimally invasive techniques suggests that laser ablation may be associated with a lower risk of recurrence compared with excisional surgery, although the included studies are heterogeneous. A systematic review by Romic et al. (2022), including 10 studies with 971 patients, reported a primary healing rate of 94.4% and a weighted mean recurrence rate of 3.8% following sinus laser-assisted closure. The authors concluded that laser treatment represents a promising option for managing chronic PD based on the published literature.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.